Kyrgyzstan’s National Interbank Processing Center Partners With Alipay+ to Launch International QR Payments
4.6.2026 04:00:00 CEST | Business Wire | Press Release
With the support of the National Bank of Kyrgyz Republic, Interbank Processing Center (IPC), Kyrgyzstan’s national payment system operator, and Alipay+, Ant International’s unified wallet gateway, have launched international QR payments for users of the ELCARD Mobile app.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260603760762/en/
(L-R) Altymysh Turatbekov, Chairman of the National Interbank Processing Center; Pan Yan, Head of Strategic Partnership for Alipay+, Ant International
The launch was officiated by the Chairman of the National Bank of the Kyrgyz Republic.
Almaz Baketaev, Chairman of the National Bank of the Kyrgyz Republic, said: “Our colleagues from IPC together with Alipay+ launched this project last year, and today we are bringing it into practice. Our citizens now have access to a payment system covering merchants worldwide. Wherever they are, they can make payments in any currency easily and without any complications. I would like to congratulate our citizens from now on, payments abroad have become truly simple and accessible.”
The launch marks a significant milestone in the continued development of Kyrgyzstan’s digital payment ecosystem and supports the country’s broader goals of advancing digital financial infrastructure and cross-border payment connectivity.
Interbank Processing Center (IPC), a subsidiary of the National Bank of the Kyrgyz Republic, is the operator of Kyrgyzstan’s national payment system. IPC plays a central role in connecting the country’s banks and financial institutions through the national ELCARD payment standard. ELCARD Mobile, the digital wallet and mobile payment application of Kyrgyzstan’s national payment system, enables users to make local card and QR payments, access digital and financial services, and now to make cross-border payments.
Altymysh Turatbekov, Chairman of the National Interbank Processing Center, said: "We are taking another significant step in the development of Kyrgyzstan's digital financial ecosystem through our partnership with Alipay+. This is a strategically important step for Kyrgyzstan's entire payments industry. It is about building a modern digital infrastructure for the country – one in which financial technologies become a natural part of everyday life: simple, seamless, and accessible regardless of borders. At IPC, our mission is not only in developing payment instruments, but in building a sustainable national digital platform capable of integrating Kyrgyzstan into the global financial ecosystem. Today's launch confirms that Kyrgyzstan is moving confidently in that direction."
Through the partnership, users in Kyrgyzstan can now make seamless cross-border payments across the Alipay+ merchant ecosystem worldwide, using the ELCARD Mobile app to pay overseas in a familiar, secure and convenient way, without the need for additional payment services or applications.
Pan Yan, Head of Strategic Partnership for Alipay+, Ant International, said: “Through our partnership with IPC, and with the support of the National Bank of Kyrgyz Republic, we are proud to help bring greater global connectivity and convenience to users in Kyrgyzstan. At Ant International and Alipay+, we believe interoperable digital payment systems are essential to enabling inclusive growth, empowering consumers and helping local economies participate more fully in global commerce.”
As travel and cross-border commerce continue to grow, interoperable payment solutions are becoming increasingly important in connecting local payment systems with the global merchant ecosystem. The partnership with IPC further expands Alipay+’s growing collaboration with national payment systems across Central Asia, the Middle East and other emerging digital economies, including HUMO in Uzbekistan, mada in Saudi Arabia and BENEFIT in Bahrain. Alipay+ also collaborates with local fintech ecosystems to drive merchant acceptance in markets like Kazakhstan, and across the United Arab Emirates and Latin America.
Today, Alipay+ connects more than 2 billion user accounts through 50 international payment partners to more than 150 million merchants across 220 destination markets worldwide, including via more than 10 national payment schemes.
About Interbank Processing Center and ELCARD
ELCARD is the national payment system of the Kyrgyz Republic, operated by the CJSC "Interbank Processing Center" (IPC). For more than 20 years, the system has been driving the development of cashless payments and connecting banks, payment organizations, and other financial institutions across the country within a unified payment ecosystem.
IPC is the operator of the National Payment System ELCARD and the Primary Operator of the National Payment System ELQR, and provides processing services for both national and international payment instruments.
The reliability and security of IPC’s services are confirmed by its compliance with the internationally recognized PCI DSS security standard.
About Alipay+
Ant International's Alipay+ is a unified wallet gateway with cross-border payment and digitisation services that help connect global merchants to consumers. Consumers enjoy seamless payments a broad choice of deals and the convenience of digital services using their preferred payment app/e-wallet while travelling abroad. Many small and medium-sized businesses already use Alipay+ digital tools to enhance efficiency and achieve omni-channel growth.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260603760762/en/
Contacts
Media Contact:
Ant International PR
pr@ant-intl.com
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Azafaros to Present at BIO International Convention 202615.6.2026 07:00:00 CEST | Press Release
Azafaros, a private company building a portfolio to become a leader in lysosomal storage disorders (LSDs), focused on addressing neurological symptoms, today announced that it will present at the 2026 BIO International Convention taking place in San Diego, USA, from June 22-25. The company’s presentation is scheduled for Monday, June 22 at 4:30 PM in Theater 4. The presentation will highlight Azafaros’ progress in developing nizubaglustat, its lead investigational compound for the treatment of rare lysosomal storage disorders with neurological involvement, including GM1 and GM2 gangliosidoses (GM1/GM2) and Niemann-Pick type C disease (NPC). Nizubaglustat is currently in two Phase 3 registrational studies (NAVIGATE) treating patients with GM1/GM2 and NPC and expects to report topline data from the studies in 2028. “BIO provides an important opportunity to update our progress as we continue advancing nizubaglustat through late-stage clinical development,” said Stefano Portolano, CEO at A
Teledyne FLIR Defense Launches Black Recon™ Autonomous Micro-Drone15.6.2026 06:05:00 CEST | Press Release
Teledyne FLIR Defense, part of Teledyne Technologies Incorporated (NYSE: TDY), today announced at Eurosatory the market launch of Black Recon™, an autonomously launched micro-drone system that delivers continuous, untethered reconnaissance from military vehicles and fixed installations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260614388428/en/ Teledyne FLIR Defense announced at Eurosatory the market launch of Black Recon™, an autonomously launched micro-drone that delivers continuous, untethered reconnaissance from military vehicles and fixed installations. Black Recon allows crews to launch, operate, recover, and recharge up to three UAS without leaving their platform, reducing operator risk. Designed for vehicle integration, Black Recon allows crews to launch, operate, recover, and recharge up to three unmanned aerial systems without leaving their platform, reducing risk and accelerating decision-making. “Black Recon
OM Pharma to Unveil the Largest Multi-Country Real-World Evidence Study on Broncho‑Vaxom® (OM‑85) for RTI Prevention at EAACI 202614.6.2026 10:00:00 CEST | Press Release
OM Pharma will reveal preliminary results from the REACH study at the European Academy of Allergy and Clinical Immunology (EAACI) Congress. REACH is the first and largest multi-country real-world evidence (RWE) study to date evaluating the impact of Broncho-Vaxom® in patients with recurrent respiratory tract infections (RTIs).1,2 The findings offer critical new clinical evidence of the therapy's effectiveness in everyday clinical practice. In a real-world cohort of 15,794 paediatric (aged >1 year), adolescent, adult and elderly patients in China, Italy, and Belgium, Broncho-Vaxom® was associated with reductions in RTI recurrence and healthcare utilisation at 12 and 24 months after treatment initiation, compared with the 12 months prior to starting the therapy.1 “The REACH real-world evidence study shows that Broncho-Vaxom® can significantly reduce infections requiring medical visits across age groups and co-morbidities,” said Anna Thomas, Chief Scientific Officer at OM Pharma. “Recurre
Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential Thrombocythemia13.6.2026 17:15:00 CEST | Press Release
Incyte (Nasdaq:INCY) today announced updated clinical data from two Phase 1 studies evaluating the safety, tolerability and efficacy of INCA033989, a first-in-class mutant calreticulin (mutCALR)-targeted monoclonal antibody, in patients with mutCALR-expressing myeloproliferative neoplasms (MPNs). INCA033989 demonstrated rapid, clinically meaningful responses and consistent molecular activity across both myelofibrosis (MF) and essential thrombocythemia (ET), with convergent evidence supporting the potential for disease modification. These findings are being presented in oral and poster presentations at the European Hematology Association (EHA) 2026 Congress in Stockholm, Sweden (Session: Myeloproliferative neoplasms – Clinical, Presentation numbers: S216, PS1983, PF884). “The data presented at EHA 2026 demonstrate clinically meaningful and consistent responses with INCA033989 across both myelofibrosis and essential thrombocythemia,” said Pablo J. Cagnoni, M.D., President of Incyte and G
Results from Incyte’s Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi ® /Minjuvi ® ) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progression Free Survival13.6.2026 12:00:00 CEST | Press Release
Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified cytolytic CD19-targeting monoclonal antibody, and lenalidomide added to R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone; Tafa-Len-R-CHOP) versus R-CHOP, the current standard of care, as a first-line treatment for adults with previously untreated diffuse large B-cell lymphoma (DLBCL) or high-grade B-cell lymphoma (HGBL). Eligible patients had an International Prognostic Index (IPI) score of 3-5, or, for patients ≤60 years of age, an age-adjusted IPI (aaIPI) of 2-3. These data are being highlighted in a prestigious Plenary Abstracts Session at the European Hematology Association (EHA) 2026 Congress, being held June 11 - 14, 2026, in Stockholm, Sweden (Abstract # S101. Plenary Abstract Session. June 13, 6:00 - 7:30 a.m. ET [12:00-1:30 p.m. CEST]). frontMIND results were als
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom